NMD Pharma A/S
- Address
- Palle Juul-Jensens Boulevard 82
Sponsor Overview
Specializations
Neuromuscular Disorders
Research activity is centred on neuromuscular disease, with studies in Charcot-Marie-Tooth disease, myasthenia gravis, and spinal muscular atrophy. The portfolio reflects a focus on conditions that affect muscle strength, mobility, and neuromuscular function.
- Charcot-Marie-Tooth disease type 1 and type 2
- Myasthenia gravis
- Type 3 spinal muscular atrophy
These programmes indicate sustained interest in disorders with impaired peripheral nerve or neuromuscular transmission, especially in adult patient populations.
Muscle Strength and Functional Outcomes
The clinical research emphasis includes muscle strength, physical function, and clinician-assessed improvement in everyday neuromuscular performance. Trial objectives point to outcomes relevant to walking ability, limb strength, and functional capacity.
- Muscle strength assessment
- Functional mobility
- Clinician-rated clinical efficacy
This area is particularly relevant for conditions where preserving or improving motor performance is a central therapeutic goal.
Peripheral Nerve and Neuromuscular Transmission Research
Work in peripheral neuropathy and neuromuscular transmission is evident from the disease mix, with attention to disorders that disrupt communication between nerves and muscles. The sponsor’s studies align with therapeutic interest in restoring neuromuscular signalling and reducing weakness.
- Peripheral neuropathy
- Neuromuscular transmission
- Motor weakness
The active trial set spans multiple countries and research sites, supporting investigation across diverse clinical settings.
Adult Rare Disease Therapeutics
The sponsored studies are directed toward adult patients living with rare, chronic neuromuscular conditions. This includes therapeutic interest in diseases with long-term functional impairment and limited treatment options.
- Rare disease neurology
- Adult patient populations
- Chronic neuromuscular impairment
The research landscape is shaped by conditions that require sustained attention to symptom burden, strength preservation, and mobility-related outcomes.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of NMD670 in Ambulatory Adults with Charcot-Marie-Tooth Disease Types 1 and 2: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial |  Belgium Denmark France Spain | Not Recruiting |
| Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults with Type 3 Spinal Muscular Atrophy: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study | Belgium Denmark Germany Italy Spain The Netherlands | Not Recruiting |
| Evaluation of NMD670 Efficacy, Safety, and Tolerability in Adult Patients with AChR/MuSK-Ab+ Myasthenia Gravis: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study | Belgium Denmark France Italy Poland Spain The Netherlands | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 40 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases2 trials449 other sponsors
- 2.Musculoskeletal Diseases1 trial238 other sponsors
Partnered Research Centres
40 centres- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Batiment Babinski Groupe 47 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Via Cherasco 15, 10126 Turin
- Address
- Piazza Luigi Miraglia 2, 80138 Naples
- Address
- Via Paradisa 2, 56124 Pisa
Want to get in touch with this sponsor?
Send a question and we'll pass it on to NMD Pharma A/S.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.